PTPRC and neoplasm: To discriminate between a systemic or tumor site‐specific effect of COMBO, we separately assessed the rate of circulating and tumor‐recruited inflammatory monocytes (CD45+Cd11b+Ly6Chigh cells; Shi & Pamer, 2011).